Navigation thread
Navigation thread
Chronic Urticaria
Make a donation
Make a donation
PortalClinic home
Joint project with BBVA Foundation website.This link opens in a new tab.

Research into Chronic Urticaria

Reading time: 1 min

In the field of chronic urticaria research, there has been a notable shift in recent years, with the emergence of new compounds.

BTK inhibitors, such as remibrutinib and rilzabrutinib, work by blocking key intracellular pathways involved in mast cell (immune cell) activation; this offers an innovative and more targeted approach to treating refractory chronic urticaria.

Other immunomodulatory agents are also being investigated, further expanding the therapeutic options for this complex condition.

Read more Treatment at Hospital Clínic
PortalClinic home
Joint project with BBVA Foundation website.This link opens in a new tab.

What is an allergy?

Consulta toda la información relacionada con Allergy

Read more
The donations that can be done through this webpage are exclusively for the benefit of Hospital Clínic of Barcelona through Fundació Clínic per a la Recerca Biomèdica and not for BBVA Foundation, entity that collaborates with the project of PortalClínic.

Subscribe

Receive the latest updates related to this content.

Thank you for subscribing!

If this is the first time you subscribe you will receive a confirmation email, check your inbox

An error occurred and we were unable to send your data, please try again later.

Chronic Urticaria related news